Back to JNGHFView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Female Subjects Undergoing COH in ART to Prevent Early Ovulation
View Full LandscapeDrug Information
Target Indication
Female Subjects Undergoing COH in ART to Prevent Early Ovulation
Clinical Trial
NCT05082233Last updated: 1/23/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
Camrelizumab plus TPPhase 3
Oral Squamous Cell Carcinoma
Remimazolam Tosilate for injectionPhase 3
Operative Sedation of Pediatric
SHR7280；Ganirelix Acetate Injection simulantPhase 3
Infertile Female Subjects Undergoing Controlled Ovarian Hyperstimulation to Suppress Premature LH Surge and Prevent Early Ovulation
TACE+Camrelizumab+Apatinib mesylatePhase 3
Hepatocellular Carcinoma
SHR2554; Chidamide analog tabletsPhase 3
Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts